However, no significant impact on prognosis was observed as a result of these mutations. In M5 subtype AML patients, PTPN11 mutations do not affect the OS of the patients. Besides, a bone marrow blast percentage ≥65.4% was identified as an independent factor influencing the OS of patients ...